FCGR2A and leukemia: Our data suggest the application of anti-iNKT TCR mAbs in the clinic to treat CD32+ tumors, such as leukemia and lymphoma, by inducing reverse ADCC, although humanization of anti-iNKT TCR mAbs might be needed.